Re-certified for CME credits, to Sept 6, 2020! The third activity in the Clinical Advances in Gene Therapy for Hemophilia CME curriculum, The Science of Gene Therapy for Hemophilia, is an expert video commentary on the vector technology behind gene therapy in hemophilia. Watch as Glenn Pierce, WFH Vice President Medical, examines early clinical trials, the challenges and breakthroughs in vector design, and emerging approaches to gene therapy in hemophilia. A transcript of the discussion as well as presentation slides containing useful illustrations, key messages and pivotal gene therapy clinical trial data enhance the learner’s comprehension of this fascinating advanced content. Learners are encouraged to study Test Your Knowledge of Gene Therapy in Hemophilia and Gene Therapy: Past, Present, and Future (see links below), prior to the third activity, in order to get the most out of this specialist presentation. Click the View Resource button to access the activity through the Medscape site. There you will have to register, which is free and straightforward.
This activity is part of the Clinical Advances in Gene Therapy for Hemophilia CME curriculum developed by the WFH in collaboration with the National Hemophilia Foundation (NHF), the European Haemophilia Consortium (EHC), and Medscape Education. These five online activities provide introductory information on gene therapy in hemophilia. While clinicians can qualify for CME credits all learners can obtain a completion certificate, or explore the activity to enhance their knowledge of gene therapy in hemophilia.
View the other activities in this curriculum:
For people considering taking gene therapy, it is extremely important to learn as much as possible about if you are
This document is an introductory guide for people with hemophilia who wish to join the World Federation of Hemophilia (WFH)
The World Federation of Hemophilia (WFH) Gene Therapy Registry (GTR) welcomes the participation of all Hemophilia Treatment Centres (HTCs) involved
This document is an introductory guide to the World Federation of Hemophilia (WFH) Gene Therapy Registry (GTR). It answers basic